Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.
- 1 January 2000
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 50 (3), 245-249
- https://doi.org/10.1023/a:1006494032052
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Single-agent docetaxel (Taxotere) in randomized phase III trials.1999
- Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas.Journal of Neuro-Oncology, 1999
- Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.Journal of Clinical Oncology, 1997
- Docetaxel.Journal of Clinical Oncology, 1995
- Salvage chemotherapy with paclitaxel for recurrent primary brain tumors.Journal of Clinical Oncology, 1995
- Paclitaxel Disposition in Plasma and Central Nervous Systems of Humans and Rats With Brain TumorsJNCI Journal of the National Cancer Institute, 1995
- Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma.1994
- Cytotoxicity of taxol in vitro against human and rat malignant brain tumorsCancer Chemotherapy and Pharmacology, 1994
- Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.1991
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990